Join our webcast for the quarterly report for the third quarter of 2025. My name is Martin. I'm the CEO of Xbrane Biopharma, and I also have with me today our CFO, Jane. We usually start by going through the operational highlights of the quarter, and then Jane will go through the financial highlights, followed by some minutes for Q&A towards the end. You can ask questions either via the audio function if you've called in or via the chat. Join our webcast concerning our quarterly report for the third quarter of 2025. So we'll start with Ximluci®, our Lucentis biosimilar, with which we have partnered. Stada has currently launched in 24 countries, out of which 20 are in Europe and four in the Asia-Middle East region. It's quite a straightforward collaboration, where we are essentially sharing the profit contribution 50/50 from the sales and marketing of this product. And just to have a look at the market situation to start with, this is a biosimilar to Lucentis with the active ingredient Ranibizumab. And we have Ximluci®, a biologic, alongside three other biosimilars to Lucentis on the market. So you can see that there's a dark blue part on the bottom representing Lucentis, the originator, as well as the Lucentis biosimilars on the market. And then if we consider the broader class of drugs, retinal anti-VEGFs, we also have the originator product, Eylea, as well as Vabysmo. And then we have certain off-label usage of the cancer drug Avastin. All in all, this is a market of about €5 billion across Europe. It has been growing at around 7% per year in volume and 5.5% in value.
And we're seeing quite a lot of developments in this market. It's a sizable market and it is growing.
However, Vabysmo, the new product launched by Roche, is also taking market share in the overall market and in the Eylea space. We are going to see biosimilars entering the market starting from the end of this year onwards.
If we look at Ximluci® and the performance of Ximluci®, we had more or less a constant volume in Q3 compared to Q2, and that is the volume that STADA sold to end customers. And market share from a volume perspective was also retained at about 8%.
Then again, that is the market share within the Ranibizumab market. So, versus Lucentis and the Lucentis biosimilars, Ximluci® is the market leader among the biosimilars in Italy and Germany. Tada! Right now, I think there are good opportunities for continued growth during next year.
There are a couple of exciting tenders where STADA is going to participate, so we do believe that the growth is going to resume during next year. And we also resumed the shipments of the product to STADA this quarter. And that will continue in the coming quarters, 5 or 6 quarters, as far as we have that forecast, if you will.
Total profit generation accumulated so far is about 150 million Swedish crowns. And we also do have an inventory of drug substance, mainly when it comes to Ximluci® amounting to about 170 million Swedish crowns. As shipments to stores are being resumed, it is being converted into cash continuously. Then switching over to the US. As most of you probably know, we unfortunately faced a delay with regards to FDA approval. We received a so-called complete response letter to our application from the FDA. And that was quite generic in terms of the stated reasons for not being able to approve the application. It mentioned that it was due to unresolved observations at one of the manufacturing sites. What then happens is that the site, which is a contract manufacturer—we don't have our own manufacturing site, so this is a contract manufacturer. Therefore, the FDA is also conscious about maintaining confidentiality. Not revealing information to us. They are not permitted by the contract manufacturer to reveal that information to us. So the site will receive more information. Soon. They haven't received it yet. Last time, we saw some information being received. Five days post CRL. So, we do expect that information to come. Yes. These days, there will essentially be more information from the FDA. What were the specific observations from the inspection they conducted? End of August, they felt were unresolved by the responses the production site submitted. We really need that information in order to be able to finalize the timing for the resubmission of the BLA. We do believe, though, that we are looking towards a resubmission in the first quarter of next year. That is based on essentially the corrective actions, which are ongoing at the production site. Following a few of the observations from the recent inspection by the FDA, are going to be finalized in the beginning of next year. And then we believe that this will be able to trigger a resubmission. But then again, we really need this information from the FDA to be able to confirm that timeline. It is then a six-month review timeline expected from a resubmission until the date, and hopefully this time around, an approval. We understand, of course, that many of you are disappointed about this, and we are also very disappointed about this outcome. It is absolutely not what we expected or had hoped for.
But we really now have to wait for information from the FDA, fully understand the issues they see, and then work together with our contract manufacturer to swiftly resolve these issues and move towards a resubmission. Let's switch gears to our next event program. Biosimilar candidate to Opdivo®. As far as we can tell, this is one out of four biosimilars to Opdivo® currently in clinic. We believe we have a timeline that will permit a launch in the US on day one, so to speak. So immediately post-patent expiration date is December 2028.
We can note here that we can go to the next slide that the clinical trial is initiated by our partner Intas. We are, on our end, going through our development responsibilities of process characterization and validation, which is a key element, of course, of an application. I think if there's one big lesson to draw from our issues with regards to Ximluci® and the FDA, it is that you should really make sure to work with manufacturing sites and contract manufacturers with a long history of successful FDA inspections and long-time supply of product to the US market. We made sure to do that for this program. We're working with one of the largest contract manufacturers globally and sites with a long history of successful FDA inspections and currently supplying product to the US market. We're doing everything we can together with our partner, Intas, to carry this development through so that we can make a submission to the FDA in the fourth quarter of 2027, allowing for approval by the end of 2028. Loss of exclusivity by the originator.
And this is a very sizable opportunity for us. We do believe it could generate a billion Swedish crowns annually. To explain, based on how historical oncology biosimilars have performed in the US and based on the profit split we have agreed with our partner, it is a very sizable opportunity for us. But of course, it hinges a lot upon a timely approval first in the US. So that's what we're fully focused on.
But I do believe that we have a timeline and a setup now which allows for that. So I'm quite excited about this program actually.
Let's switch gears to our next event program. So with that said, I'm going to hand over to Jane to go through the financials.